الفهرس 
Introduction and Aim of workOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
Background and aim:Platinum-based chemotherapy (PBC) could be a possible treatment for TNBC.ERCC1 immunostaining can be utilized to predict the results in patients who recieving PBC. Only a few reports have discussed the function of claudins in TNBC, and their function sill debatable. Ki-67 is a biomarker that test sensitivity of chemotherapy in breast cancer. Our aim was to assess the expression of ERCC1, claudin-4 & Ki-67 in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy (paclitaxel and Carboplatin).Patients and methods: The study is a prospective non-Comparative, to assess the relationship among ERCC1, Claudin -4, Ki- 67 expression and response to platinum based chemotherapy, also to estimate predictive value of those biomarkers in metastatic/recurrent TNBC of thirty (30) histologically confirmed metastaic/recurrent TNBC patients who presented at outpatient clinic of Medical Oncology unit at Oncology Center Mansoura University between January 2015 and January 2018.The collected data was revised, coded and tabulated using Statistical package for Social Science Results: After follow up period of 42 months, thirty cases of metastatic TNBC had received paclitaxel/carboplatin (ORR 43.3 %) with accepted toxicity profile. Patients with negative/low ERCC1 expression had much more better responses (more frequent PR or better) with PFS & OS of 22 & 30 months respectively while those with moderate/high expression more patients began to show progressive disease and became less likely to attain PR or better response with PFS & OS of 15 &17 months respectively (p value was significant). Patients with negative/low Claudin-4 expression had much more better responses (more frequent PR or better) with PFS & OS of 24 & 34 months respectively while those with moderate/high expression more patients began to show progressive disease and became less likely to attain PR or better response with PFS & OS of 14 &17 months respectively (p-value was significant). Patient with high Ki-67 had more aggressive disease with shorter PFS & OS of 18.5 & 22 months vs not reached &24 months or those with low Ki-67 respectively (however, not significant).